Investors

Corporate Profile

Xtant Medical Holdings, Inc. (NYSE MKT: XTNT) develops, manufactures and markets regenerative medicine products and medical devices for domestic and international markets. Xtant products serve the specialized needs of orthopedic and neurological surgeons, including orthobiologics for the promotion of bone healing, implants and instrumentation for the treatment of spinal disease, tissue grafts for the treatment of orthopedic disorders, and biologics to promote healing following cranial, and foot and ankle surgeries.


Stock Quote
XTNT (Common Stock)
Price$0.78
Change (%)0.00 (0.00%)
Volume0
Data as of 07/26/17 3:59 p.m. ET
Refresh quote

Data provided by Nasdaq. Minimum 15 minutes delayed.

Stock Chart


Recent News
DateTitle 
07/24/17Xtant Medical to Announce Second Quarter 2017 Results on August 9th, 2017
BELGRADE, Mont., July 24, 2017 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE MKT:XTNT), a leader in the development of regenerative medicine products and medical devices, today announced that it will release its financial results for the second quarter ended June 30, 2017, after the close of the financial markets on Wednesday, August 9, 2017. An accompanying conference call will be conducted by Carl O'Connell, Chief Executive Officer and President, and John Gandolfo, Chief Financia... 
05/26/17Xtant Medical Announces Rescheduling of Annual Meeting
BELGRADE, Mont., May 26, 2017 (GLOBE NEWSWIRE) -- Xtant™ Medical Holdings, Inc. (NYSE MKT:XTNT), a leader in the development of regenerative medicine products and medical devices, today announced that its board of directors has rescheduled the Company's annual meeting of stockholders, originally scheduled for June 21, 2017, to a later date, as the Company continues to evaluate its strategic alternatives. The Company will announce a new annual meeting date and record date when they are determin... 
05/16/17Xtant Medical Enters into Licensing Agreement for Sites Medical’s OsteoSync Ti Technology
BELGRADE, Mont., May 16, 2017 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE MKT:XTNT), a leader in the development, manufacturing and marketing of orthopedic products for domestic and international markets, today announced it has entered into a licensing agreement with Sites Medical LLC, for utilization of their proprietary OsteoSync™ Ti technology, a best-in-class porous titanium scaffold. "We are very excited to work with Sites Medical," said Carl O'Connell, CEO of Xtant Medical.... 
05/12/17Xtant Medical Announces OrbiMed Financing and Engagement of Aurora Management Partners
BELGRADE, Mont., May 12, 2017 (GLOBE NEWSWIRE) -- Xtant™ Medical Holdings, Inc. (NYSE MKT:XTNT), a leader in the development of regenerative medicine products and medical devices, today announced it has entered into an amendment to its senior credit facility with affiliates of OrbiMed Advisors (“OrbiMed”) for a financing of up to $15 million with the proceeds being used to pay off its outstanding balance of approximately $9 million under its accounts receivable credit facility with Silicon Val... 
More


Upcoming Events
DateTitle
08/10/17 10:00 a.m. ET
Q2 2017 Xtant Medical Holdings Inc Earnings Conference Call
More

Receive Email Alerts
Sign up to receive email alerts whenever Xtant Medical Holdings Inc posts new information to the site. Just enter your email address and click Submit.